NCT03065218View on ClinicalTrials.gov

99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions
Thyroid Cancer
Interventions
DRUG

99mTc sestamibi

The administration of the diagnostic radioisotope, 99mTc sestambi, to image possible metastases in patients with differentiated thyroid cancer.

Trial Locations (1)

20010

Washington Hospital Center, Washington D.C.

Sponsors
All Listed Sponsors
lead

Medstar Health Research Institute

OTHER